Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says

Executive Summary

Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call

You may also be interested in...



Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies

Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions

Merck Singulair Presents Managed Care Test: Covering Asthma, Not Allergies

Merck's Singulair approval in allergic rhinitis presents a challenge for managed care to differentiate between the drug's existing asthma indication and its use in allergies when making coverage decisions

Singulair Advantage In Allergies Is Leukotriene-Blocking Action, Merck Says

Merck's Singulair AR novel mechanism of action allows the asthma drug to work across multiple allergic rhinitis symptoms, Human Health President-Americas David Anstice told investors

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel